Canada - anglais - Health Canada

taro pharmaceuticals inc - calcitriol - capsule - 0.5mcg - calcitriol 0.5mcg - vitamin d

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol rm is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol rm is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol rm is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol sg is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol sg is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol sg is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol kp is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol kp is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol kp is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol cw is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol cw is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol cw is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxyanisole; iron oxide yellow; fractionated coconut oil; butylated hydroxytoluene; gelatin; iron oxide red; purified water - calcitriol-ga is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calcitriol-ga is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calcitriol-ga is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

États-Unis - anglais - NLM (National Library of Medicine)

fosun pharma usa inc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. it has been shown to significantly reduce elevated parathyroid hormone levels. reduction of pth has been shown to result in an improvement in renal osteodystrophy. calcitriol injection should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. calcitriol injection is contraindicated in patients with previous hypersensitivity to calcitriol or any of its excipients.

États-Unis - anglais - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol oral solution administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manif

États-Unis - anglais - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.5 ug

États-Unis - anglais - NLM (National Library of Medicine)

kaiser foundation hospitals - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug